FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:840-842 February 21, 2008 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schneeweiss, S. Related Article by Shaw, A. D. PubMed Citation

Aprotinin, a hemostatic agent that inhibits the fibrinolytic enzyme plasmin,¹ was approved by the Food and Drug Administration (FDA) in 1993 for reducing blood loss during coronary-artery bypass grafting (CABG). By 2006, aprotinin was prescribed for approximately 200,000 patients undergoing cardiac surgery worldwide.² Aminocaproic acid and tranexamic acid are lysine analogues that inhibit the binding of fibrin to plasminogen and also reduce blood loss, but a specific indication for bypass grafting is not included on their labels.¹ The safety of aprotinin was called into question in 2006 and 2007, when the results of an international cohort study by Mangano et . . . [Full Text of this Article]

Source Information

From the Vanderbilt Center for Education and Research on Therapeutics, Department of Preventive Medicine, Vanderbilt University School of Medicine and the Geriatric Research, Education, and Clinical Center, Nashville Veterans Affairs Medical Center — both in Nashville.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.